-
Mashup Score: 8ESC 23: NOAH-AFNET 6: Oral Anticoagulation in Pts With AHRE - 8 month(s) ago
ESC 2023 — Prof Paulus Kirchhof (University Heart & Vascular Center Hamburg, DE) discusses the findings of the NOAH-AFNET 6 trial (NCT02618577). NOAH-AFNET 6 (Atrial
Source: www.aerjournal.comCategories: Latest Headlines, Partners & KOLsTweet
-
Mashup Score: 1
Original Article from The New England Journal of Medicine — Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes
Source: www.nejm.orgCategories: Cardiologists, Latest HeadlinesTweet-
Anticoagulation with #Edoxaban in Patients with Atrial High-Rate Episodes #NOAH #AFNET #ESCCongress https://t.co/o4dk79ojiX
-
-
Mashup Score: 0
Abstract Background Standard of care (SOC) anticoagulation for thromboembolism (TE) prevention in children with cardiac disease includes low molecular weight heparins or vitamin K antagonists. Limi…
Categories: Cardiac Surgery, Latest HeadlinesTweet-
The #ENNOBLE-ATE trial was an international multi-center randomized trial comparing oral once daily #edoxaban vs standard of care anticoag in children w/ heart disease. Results suggest edoxaban is safe/effective in children less than 18 years of age. https://t.co/rdYJKGCMRz #JACC https://t.co/TC1QbFZCeD
-
-
Mashup Score: 0
CHICAGO — For children with rare heart conditions that increase risk for thromboembolism, daily edoxaban may be a safe and effective alternative compared with the current standard of care for this age group, researchers reported. Edoxaban (Savaysa, Daiichi Sankyo) is FDA-approved for use in adults with atrial fibrillation and other conditions that increase risk for thromboembolism.
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
For children with rare heart conditions that increase risk for #thromboembolism, daily #edoxaban may be a safe and effective alternative vs. current standard of care for this age group @MPortmanMD @seattlechildren @AHAMeetings #AHA22 #cardiotwitter https://t.co/Kji8grYOsX
-
-
Mashup Score: 2Edoxaban for stroke prevention in atrial fibrillation and age-adjusted predictors of clinical outcomes in routine clinical care - 2 year(s) ago
AbstractIntroduction. Patients with atrial fibrillation (AF) treated with oral anticoagulation still suffer from cardiovascular complications including cardiova
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
#Edoxaban for stroke prevention in atrial fibrillation and age-adjusted predictors of clinical outcomes. Congratulations to all authors especially our friend and expert JC Deharo. He will be @CNCFCardio congress https://t.co/mER1nNUcXT
-
-
Mashup Score: 1Edoxaban does not impact outcomes after TAVR vs. DAPT - 2 year(s) ago
WASHINGTON — In the ADAPT-TAVR trial of patients who had transcatheter aortic valve replacement and no indication for long-term anticoagulation, edoxaban did not improve leaflet thrombosis compared with dual antiplatelet therapy.There was also no difference between the edoxaban (Savaysa, Daiichi Sankyo) and DAPT groups in cerebral thromboembolism and neurological or neurocognitive function,
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
In ADAPT-TAVR, patients who had #TAVR and no indication for long-term anticoagulation, #edoxaban did not improve leaflet thrombosis compared with DAPT @dukwoo_park @ACCinTouch #ACC22 #Cardiotwitter https://t.co/ViVMANPdTb
-
-
Mashup Score: 0Edoxaban in Older Patients With Atrial Fibrillation - 2 year(s) ago
This randomized clinical trial investigates the effect of 15-mg edoxaban in patients aged 80 years and older who are not candidates for standard-dose oral anticoagulants owing to bleeding risk.
Source: jamanetwork.comCategories: Cardiologists, Latest HeadlinesTweet-
#Edoxaban in Older Patients With #AtrialFibrillation #Geriatrics #AFib https://t.co/OnASpRUf1v via @JAMACardio part of @JAMANetwork
-
-
Mashup Score: 2
The ELDERCARE-AF trial (The Edoxaban Low-Dose for Elder Care in AF Patients) demonstrated that a once-daily 15-mg dose of edoxaban was superior to placebo in preventing stroke or systemic embolism and did not result in a significantly higher incidence of major bleeding than placebo in very elderly Japanese patients with nonvalvular atrial fibrillation (NVAF) who were not appropriate candidates…
Source: CirculationCategories: Cardiologists, Latest HeadlinesTweet-
In this subanalysis of the ELDERCARE-AF Trial, #edoxaban 15 mg ⬇️ the incidence of #stroke/systemic embolism regardless of the level of #renal dysfunction, & there was no ⬆️ in intracranial haemorrhage or fatal #bleeding events in the edoxaban group. https://t.co/oEeYLwkOPA
-
-
Mashup Score: 1
Original Article from The New England Journal of Medicine — Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR
Source: New England Journal of MedicineCategories: Cardiologists, Latest HeadlinesTweet-
Post #TAVR w #Afib:Primary outcome occurred in 170 pts in #edoxaban group;157 in #warfarin group (HR, 1.05; 95% CI, 0.85 to 1.31; P=0.01 for NI). Major bleeding, mostly more GIB, was higher in edoxaban group (HR, 1.40; 95% CI, 1.03 to 1.91; P=0.93 for NI) https://t.co/wGBX1FFADA
-
-
Mashup Score: 6
In the ENVISAGE-TAVI AF trial, edoxaban was noninferior to vitamin K antagonists for adverse clinical events and was associated with increased major bleeding in patients with AF who underwent transcatheter aortic valve replacement.The increase in major bleeding was primarily driven by gastrointestinal bleeding in the edoxaban (Savaysa, Daiichi Sankyo) group. Incidence of intracranial hemorrhage
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
ENVISAGE-TAVI AF: #Edoxaban was noninferior to vitamin K antagonists for adverse clinical events and was associated with increased major bleeding in patients with AF who underwent #TAVR @IcahnMountSinai #ESCCongress @escardio @ESCardioNews #Cardiotwitter https://t.co/XXvcV4QOpy
-
🫀NEW #ESCCongress Hot Line Interview 💫Prof Paulus Kirchhof discusses major findings from NOAH-AFNET 6. 📽️👉 https://t.co/Xv089OClDq 📊NOAC #edoxaban in pts with atrial high-rate episodes increased bleeding without reducing a composite of stroke, systemic embolism or CV death. https://t.co/1xp0SEHlNU